What Nyxoah SA does.

We are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA. Our lead solution is the Genio system, a CE-Marked and FDA approved, patient-centric next generation hypoglossal neurostimulation, or HGNS, therapy for the treatment of moderate to severe OSA, implanted via a single-incision procedure. OSA is the world’s most common sleep disordered breathing condition and is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Our technology platform is a first-of-its-kind HGNS device designed to treat OSA through bilateral stimulation, by maintaining upper airway patency to reduce obstructive breathing events during sleep. We started generating revenue from the sale of the Genio system in Europe in July 2020. On August 8, 2025, the FDA approved the Genio system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index, or AHI, of greater than or equal to 15 and less than or equal to 65, and we started generating revenue from the sale of the Genio system in the U.S. in September 2025. We are building a growing body of clinical evidence to further support the strong value proposition of the Genio system and its ability to improve the health and quality of life of OSA patients.

Revenue and profit, by fiscal year.

More on NYXH.

• Nyxoah SA summary
• Nyxoah SA financial statements
• Nyxoah SA key metrics
• Nyxoah SA health scores and style box
• Nyxoah SA earnings
• Nyxoah SA dividends
• Nyxoah SA valuation
• Nyxoah SA ownership and insiders
• Nyxoah SA peers

Figures from Nyxoah SA's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.